Ireland - English - HPRA (Health Products Regulatory Authority)

ct arzneimittel gmbh - simvastatin - film coated tablet - 40 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ct arzneimittel gmbh - simvastatin - film coated tablet - 10 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ct arzneimittel gmbh - simvastatin - film coated tablet - 20 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ct arzneimittel gmbh - simvastatin - film coated tablet - 40 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ct arzneimittel gmbh - simvastatin - film coated tablet - 5 milligram

United States - English - NLM (National Library of Medicine)

stat rx usa - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram hydrobromide 10 mg - citalopram hbr is indicated for the treatment of depression. the efficacy of citalopram hbr in the treatment of depression was established in 4-6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficacy of citalop

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 20 mg - citalopram tablets, usp are indicated for the treatment of depression. the efficacy of citalopram in the treatment of depression was established in 4 to 6 week; controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram tablets, usp in hospitalized depressed patients has not been adequately studied. the efficacy

United States - English - NLM (National Library of Medicine)

bracco diagnostics inc - iopamidol (unii: jr13w81h44) (iopamidol - unii:jr13w81h44) - iopamidol 408 mg in 1 ml - isovue-m (lopamidol injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (cect) cisternography and ventriculography. isovue-m 200 (lopamidol injection) is indicated for thoraco-lumbar myelography in children over the age of two years. intrathecal administration of corticosteroids with iopamidol is contraindicated. because of overdosage considerations, immediate repeat myelography in the event of technical failure is contraindicated (see interval recommendation under dosage and administration ). myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely.

United States - English - NLM (National Library of Medicine)

bipso gmbh - iopamidol (unii: jr13w81h44) (iopamidol - unii:jr13w81h44) - iopamidol 408 mg in 1 ml - isovue (lopamidol injection) is indicated for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (cect) head and body imaging (see below). isovue may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. isovue may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. the usefulness of contrast enhancement for the investigation of the r

United States - English - NLM (National Library of Medicine)

liebel-flarsheim company llc - iothalamate meglumine (unii: xuw72gop7w) (iothalamic acid - unii:16chd79mix) - iothalamate meglumine 430 mg in 1 ml - conray 43 is indicated for use in lower extremity venography, intravenous infusion urography, contrast enhancement of computed tomographic brain images and arterial digital subtraction angiography. conray 43 may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space. continuous or multiple scans separated by intervals of 1 to 3 seconds during the first 30 to 90 seconds post-injection of the contrast medium (dynamic ct scanning) may provide enhancement of diagnostic significance, and may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with ct alone and in supplying additional features of the lesions. in other cases, the contrast agent may allow visualization of lesions not seen with ct alone, or may help to define suspicious lesions seen with unenhanced ct (see clinical pharmacology). su